Gene: KIR3DL2

3812
3DL2|CD158K|KIR-3DL2|NKAT-4|NKAT4|NKAT4B|p140
killer cell immunoglobulin like receptor, three Ig domains and long cytoplasmic tail 2
protein-coding
19q13.42
Ensembl:ENSG00000240403 MIM:604947 Vega:OTTHUMG00000065935 UniprotKB:P43630
NG_012802.1
SNP Mapped
AD
0   
NA (AD)  NA (ND)   (Frontal_Cortex)
5.126e-1 (AD)  5.594e-2 (ND)

ANCO-SNPs

SNP ID Position Alleles Trait Variation Type
rs3826878chr19:54865756 (GRCh38.p7)A>G / A>Talcohol dependenceSNV(Single Nucleotide Variation)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
LCE3B0.375
HOXD40.351
PRELP0.336
ASPN0.325
AMBP0.319
MRC10.315
C16orf970.314
OR2G30.312
CD40.311
DPEP30.31

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
MAP1LC3B2-0.275
MND1-0.263
DDX4-0.245
PSTK-0.232
RNF39-0.226
CHAF1A-0.225
PTRH2-0.223
RASGEF1B-0.222
C16orf92-0.22
PTTG1-0.22

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C0095054,4'-diaminodiphenylmethane"4,4'-diaminodiphenylmethane results in increased expression of KIR3DL2 mRNA"18648102
D018501Antirheumatic AgentsAntirheumatic Agents results in decreased expression of KIR3DL2 mRNA24449571
D001151ArsenicArsenic affects the expression of KIR3DL2 mRNA18414638
D001548Benzalkonium CompoundsBenzalkonium Compounds results in decreased expression of KIR3DL2 mRNA25377654
C006780bisphenol Abisphenol A results in increased methylation of KIR3DL2 promoter27312807
D018817N-Methyl-3,4-methylenedioxyamphetamine"N-Methyl-3,4-methylenedioxyamphetamine results in decreased expression of KIR3DL2 mRNA"20188158
D017830OctoxynolOctoxynol results in decreased expression of KIR3DL2 mRNA25377654
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin promotes the reaction [AHR protein binds to KIR3DL2 promoter]19654925
D014635Valproic AcidValproic Acid results in increased methylation of KIR3DL2 gene29154799
D014635Valproic AcidValproic Acid affects the expression of KIR3DL2 mRNA17292431
D019287Zinc SulfateZinc Sulfate results in decreased expression of KIR3DL2 mRNA16330358

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0005515protein binding-IPI24018270  27455421  
GO ID GO Term Qualifier Evidence PubMed
GO:0006968cellular defense response-TAS7716543  
GO:0050776regulation of immune response-TAS-  
GO ID GO Term Qualifier Evidence PubMed
GO:0005886plasma membrane-TAS-  
GO:0005887integral component of plasma membrane-TAS7716543  
KEGG ID KEGG Term
hsa04612Antigen processing and presentation
hsa04650Natural killer cell mediated cytotoxicity
hsa05332Graft-versus-host disease
Reactome ID Reactome Term Evidence
R-HSA-1280218Adaptive Immune SystemTAS
R-HSA-168256Immune SystemTAS
R-HSA-198933Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cellTAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal